Last reviewed · How we verify
MK 6240
At a glance
| Generic name | MK 6240 |
|---|---|
| Sponsor | Tammie L. S. Benzinger, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD (PHASE3)
- Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK 6240 CI brief — competitive landscape report
- MK 6240 updates RSS · CI watch RSS
- Tammie L. S. Benzinger, MD, PhD portfolio CI